TD52

TD52 is a small molecule that serves as a selective inhibitor of cancerous inhibitor of protein phosphatase 2A (CIP2A), a known oncoprotein implicated in immune regulation and tumor progression. TD52 is a derivative of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and exhibits potent antitumor efficacy against hepatocellular carcinoma (HCC) and triple-negative breast cancer (TNBC) cells. Mechanistically, TD52 induces apoptosis in tumor cells and promotes macrophage autophagy by blocking the AKT-mTOR signaling pathway. It has also been shown to reduce inflammatory cytokine production and alleviate pathological symptoms in models of severe acute pancreatitis by modulating macrophage activation. The compound is being investigated as a research tool and a potential therapeutic in oncology and inflammatory diseases.[1][2][3][4][6]

Other names

TD52 dihydrochlorideTD-52 dihydrochlorideTD 52 dihydrochloride